Lv3
228 积分 2021-01-11 加入
Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications
20天前
已完结
52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial
21天前
已完结
Evolving landscape of JAK-STAT inhibition in the treatment of immune-mediated inflammatory diseases
26天前
已完结
Characterizing the willingness to undergo treatment in patients with alopecia areata
1个月前
已完结
Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors
1个月前
已完结
A two phase regulation of bone regeneration: IL-17F mediates osteoblastogenesis via C/EBP-β in vitro
1个月前
已完结
Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update
2个月前
已完结
HR+/HER-2-早期乳腺癌复发风险与临床管理专家共识（2025版）
2个月前
已完结
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial
2个月前
已完结
皖公网安备34019202002308
